ERBB2 and neoplasm: The discordance of HER2 status on tumor tissues and CTCs was present (38%—86%) (Fehm et al., 2007; Fehm et al., 2010; Munzone et al., 2010; Zhang et al., 2016; Chen et al., 2019).